Kuros Biosciences AG's (VTX:KURN) market cap dropped CHF107m last week; Individual investors bore the brunt The considerable ownership by individual investors in Kuros Biosciences indicates that they ...

His extensive F&A expertise and proven success in launching transformative medical technologies align seamlessly with our vision," said Chris Fair, Chief Executive Officer of Kuros Biosciences.

Formation of a dedicated Surgeon Advisory Board to shape clinical and commercial strategies for MagnetOs TM in extremities markets ZURICH, SWITZERLAND / ACCESSWIRE / November 19, 2024 / Kuros ...

Kuros Biosciences AG / Key word (s): Miscellaneous/Personnel Kuros Biosciences Expands into Extremities Markets 19.11.2024 / 07:00 CET/CEST ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The remaining part of Kuros Therapeutics continued in a new company named Kuros Biosurgery, which in January 2016 acquired Cytos Biotechnology in a reverse IPO and changed its name to Kuros ...